Alkem Laboratories Ltd. v. Nava Healthcare Pvt. Ltd. & Ors.

In the high-stakes world of pharmaceuticals, where a single trademark can be worth millions and patient safety hangs in the balance, the temptation to slam the courtroom doors shut on a competitor is enormous. But what happens when a court refuses to play along? The Delhi High Court's decision in the Alkem Laboratories vs. Nava Healthcare dispute is a masterclass in why speed alone cannot override fairness, especially when medicine bottles — and the public's health — are on the line.

Alkem Laboratories Ltd, an established name in the pharmaceutical industry, found itself in a trademark dispute with Nava Healthcare Pvt. Ltd. and others. The conflict centered on pharmaceutical products, a sector where brand confusion can have life-altering consequences for patients. Believing its trademark rights were being infringed, Alkem Laboratories approached the Delhi High Court seeking an immediate ex parte interim injunction — essentially asking the judge to rule in its favor without even hearing the other side. The stakes were clear: an ex parte order could have frozen Nava Healthcare's operations overnight.

Alkem Laboratories argued that its trademark rights were being violated and pushed for urgent judicial intervention, requesting that the court act before the defendants could even mount a defense. On the other side, Nava Healthcare raised a critical counter-argument: it claimed prior use of the mark dating back to 2018. This was not a trivial claim — if true, it would mean Nava Healthcare had been operating in the market long before any alleged infringement began. Beyond the commercial dispute, the court also weighed a deeper concern: public interest in pharmaceutical quality. When medicines are involved, courts recognize that abruptly halting one company's production can disrupt supply chains and affect patient access to essential drugs.

The Delhi High Court declined to grant the ex parte interim injunction that Alkem Laboratories had sought. The court's reasoning was grounded in two key considerations. First, the defendants had raised a credible claim of prior use since 2018, which needed to be examined properly rather than dismissed out of hand. Second, the court emphasized that public interest — particularly in the context of pharmaceutical products and their quality — demanded that the defendants be given a fair opportunity to present their case. Rather than issuing a sweeping order, the court took the more measured step of issuing notice to the defendants, allowing the litigation to proceed with both sides having their day in court. The outcome was mixed: Alkem's urgent plea was denied, but the door remained open for the dispute to be fully argued on its merits.

For founders and IP professionals, this case delivers a clear and practical lesson: do not assume that an ex parte injunction is a guaranteed weapon in your IP arsenal, especially in sensitive sectors like pharmaceuticals. Courts will hesitate to grant one-sided orders when the defendant raises a credible prior use defense or when public interest is at stake. The smarter play is to build a thorough evidentiary record from day one, document your trademark use meticulously, and be prepared for a full adversarial hearing rather than banking on a quick courtroom knockout. In pharma and other regulated industries, patience and preparation often beat panic.